← Leaderboards
Matthias Johannes Schnell
Univ Of Maryland, College Park
$34,760,060
Attributed
$39,475,179
Total exposure
30
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,475,179 · 30
By mechanism
R01$19,782,996 · 8
N01$5,986,062 · 1
R21$3,385,526 · 8
P01$2,676,279 · 1
R42$2,509,160 · 1
P30$1,835,032 · 1
Top collaborators
- Utpal Pal5 shared
- Luis J. Sigal5 shared
- Dennis A Bente4 shared
- Richard K. Plemper3 shared
- Glenn F Rall2 shared
Others in their field
Top investigators on “Rabies Virus”
- Hongkui Zeng · Allen Institute$35,086,747
- Peter L Strick · University Of Minnesota Twin Cities$30,057,059
- Edward M Callaway · Salk Institute For Biological Studies$27,813,020
- Sean P. J. Whelan · Washington University$12,737,522
- Joseph R Ecker · University Of California, San Diego$12,115,232
- Ian R Wickersham · Massachusetts Institute Of Technology$10,908,321
Research focus
Rabies VirusVaccinesImmunogenicityImmune ResponseRecombinantsBaseVirusViralResponseImmunityVectorVaccine DevelopmentVector VaccineCommunicable DiseasesInfectionVirus DiseasesVirionAntigensRabiesImmunizationProteinsAnimalsImmunizeLaboratories
Grant awards (73)
Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever$3,347,060
N01 · FY2025 · AI · contact PI
Shared Resource Management$949,714
P30 · FY2025 · CA · contact PI
Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models$788,659
R01 · FY2025 · AI · contact PI
Multivalent Tick-Microbe targeted Lyme disease vaccines$698,515
R01 · FY2025 · AI
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses$378,300
R01 · FY2025 · AI · contact PI
Shared Resource Management$885,318
P30 · FY2024 · CA · contact PI
Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models$788,347
R01 · FY2024 · AI · contact PI
Multivalent Tick-Microbe targeted Lyme disease vaccines$707,645
R01 · FY2024 · AI
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses$390,000
R01 · FY2024 · AI · contact PI
Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models$788,347
R01 · FY2023 · AI · contact PI
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses$390,000
R01 · FY2023 · AI · contact PI
Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models$779,687
R01 · FY2022 · AI · contact PI
Multivalent Tick-Microbe targeted Lyme disease vaccines$716,967
R01 · FY2022 · AI
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer$164,930
T32 · FY2022 · AI
Multivalent Tick-Microbe targeted Lyme disease vaccines$712,910
R01 · FY2021 · AI
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses$390,000
R01 · FY2021 · AI · contact PI
Development of a single-dose rabies virus vaccine$390,000
R01 · FY2021 · AI · contact PI
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer$223,821
T32 · FY2021 · AI
Multivalent Tick-Microbe targeted Lyme disease vaccines$707,956
R01 · FY2020 · AI
Toward a protective Covid-19 vaccine utilizing an established vector platform$429,000
R21 · FY2020 · AI · contact PI
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses$390,000
R01 · FY2020 · AI · contact PI
Development of a single-dose rabies virus vaccine$390,000
R01 · FY2020 · AI · contact PI
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer$222,539
T32 · FY2020 · AI
Drug discovery against lyssaviruses by high thoughput screening$398,340
R01 · FY2019 · AI · contact PI
Development of a single-dose rabies virus vaccine$390,000
R01 · FY2019 · AI · contact PI
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer$244,397
T32 · FY2019 · AI
Development of Rabies-based Virus-like Particles$234,000
R21 · FY2019 · AI · contact PI
Drug discovery against lyssaviruses by high thoughput screening$384,375
R01 · FY2018 · AI · contact PI
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer$237,779
T32 · FY2018 · AI
Toward an Pan-lyssavirus vaccine$234,000
R21 · FY2018 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$2,639,002
N01 · FY2017 · AI · contact PI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine$831,383
R01 · FY2017 · AI · contact PI
Drug discovery against lyssaviruses by high thoughput screening$398,375
R01 · FY2017 · AI · contact PI
Toward an Pan-lyssavirus vaccine$195,000
R21 · FY2017 · AI · contact PI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine$1,090,934
R01 · FY2016 · AI · contact PI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine$1,203,246
R01 · FY2015 · AI · contact PI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine$945,119
R01 · FY2014 · AI · contact PI
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.$833,079
R42 · FY2014 · AI · contact PI
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine$949,716
R01 · FY2013 · AI · contact PI
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.$858,482
R42 · FY2013 · AI · contact PI
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.$817,599
R42 · FY2012 · AI · contact PI
Fate of neurons following immune-mediated viral clearance$205,650
R21 · FY2012 · NS · contact PI
Fate of neurons following immune-mediated viral clearance$261,000
R21 · FY2011 · NS · contact PI
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$57,750
P51 · FY2011 · RR · contact PI
Functional Analysis of NSV-based HIV vectors$1,314,171
P01 · FY2010 · AI · contact PI
Bat rabies virus in its natural host$208,532
R21 · FY2010 · AI · contact PI
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$61,801
P51 · FY2010 · RR · contact PI
Functional Analysis of NSV-based HIV vectors$1,362,108
P01 · FY2009 · AI · contact PI
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.$336,589
R41 · FY2009 · AI · contact PI
Bat rabies virus in its natural host$188,269
R21 · FY2009 · AI · contact PI
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$58,149
P51 · FY2009 · RR · contact PI
Rabies Virus-Based Vectors as an HIV-1 Vaccine$694,898
R01 · FY2008 · AI · contact PI
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.$332,811
R41 · FY2008 · AI · contact PI
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$63,253
P51 · FY2008 · RR · contact PI
Rabies Virus-Based Vectors as an HIV-1 Vaccine$701,155
R01 · FY2007 · AI · contact PI
A novel rhabdovirus-based anthrax vaccine$546,418
R41 · FY2007 · AI · contact PI
Astrocytes and Restricted HIV-1 Replication$349,049
R01 · FY2007 · MH · contact PI
A novel rhabdovirus-based anthrax vaccine$521,247
R41 · FY2006 · AI · contact PI
Rabies Virus-Based Vectors as an HIV - 1 Vaccine$378,141
R01 · FY2006 · AI · contact PI
Astrocytes and Restricted HIV-1 Replication$359,474
R01 · FY2006 · MH · contact PI
Killed Rhabdoviruses as Novel Anthrax Vaccines$190,418
R21 · FY2006 · AI · contact PI
IMMUNOGENICITY STUDIES OF RABIES VIRUSES EXPRESSING HIV-1 OR SIV$65,435
P51 · FY2006 · RR · contact PI
Killed Rhabdoviruses as Novel Anthrax Vaccines$234,000
R21 · FY2005 · AI
Rabies Virus-Based Vectors as an HIV - 1 Vaccine$228,208
R01 · FY2005 · AI
IMMUNOGENICITY STUDIES OF RABIES VIRUSES EXPRESSING HIV-1 OR SIV$54,500
P51 · FY2005 · RR
Rabies Virus-Based Vectors as an HIV -1 Vaccine$378,503
R21 · FY2004 · AI
IMMUNOGENICITY: RABIES VIRUSES EXPRESSING HIV-1 OR SIV$47,161
P51 · FY2004 · RR
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$357,750
R01 · FY2003 · AI
Prime/Boost Immunization against HIV-1 by Viral Vectors$292,865
R21 · FY2003 · AI
IMMUNOGENICITY STUDIES OF RABIES VIRUSES EXPRESSING HIV-1 OR SIV$61,544
P51 · FY2003 · RR
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$357,750
R01 · FY2002 · AI
Prime/Boost Immunization against HIV-1 by Viral Vectors$334,289
R21 · FY2002 · AI
RABIES VIRUS-BASED VECTORS AS AN HIV-1 VACCINE$357,750
R01 · FY2001 · AI